Jaguar Health Files 8-K on Equity Sales
Ticker: JAGX · Form: 8-K · Filed: May 2, 2025 · CIK: 1585608
Sentiment: neutral
Topics: equity-sale, filing
TL;DR
Jaguar Health sold unregistered equity, check for dilution.
AI Summary
On April 30, 2025, Jaguar Health, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also includes financial statements and exhibits, with the report being filed as of May 2, 2025. The company, formerly known as Jaguar Animal Health, Inc., is incorporated in Delaware and headquartered in San Francisco, California.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the unregistered sale of equity securities, which could impact the stock price.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and signal potential financial distress or a need for capital.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- Jaguar Animal Health, Inc. (company) — Former company name
- April 30, 2025 (date) — Date of earliest event reported
- May 2, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- San Francisco, California (location) — Principal executive offices
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type or amount in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported was on April 30, 2025.
What is Jaguar Health, Inc.'s principal executive office address?
The principal executive offices are located at 200 Pine Street Suite 400, San Francisco, California, 94104.
What was Jaguar Health, Inc. formerly known as?
The company was formerly known as Jaguar Animal Health, Inc.
What is the SIC code for Jaguar Health, Inc.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding Jaguar Health, Inc. (JAGX).